"The current microcap and biotech funding climate is making raising capital very challenging and keeping up with the considerable expense of public company operations and professional fees has resulted in them not being able to timely file or annual report. The company is working on remedying that as soon as possible"
Not a good way to finish a PR...tailing off, spelled "our" wrong, left a period off the final sentence, lol...sell an asset. SELL SOMETHING. Number one priority is to get a SALESFORCE that can sell the one product that they have FDA approval on...JMO
Need funding for the salesforce, though. So MONEY is the still the number one priority.
News 
Market Data 
Discover 
AI
